PERSPECTIVES
CONTEMPORARY APPROACH IN BLEEDING AND TRAUMA COAGULOPATHY MANAGEMENT: FIBRINOGEN AS A MAGIC BULLET

UDK: 616-005.1-085.273.53

Naumovski F1, Trposka PA1, Ognjanova SV1

1 University Clinic for Traumatology, Orthopedics, Anesthesia, Reanimation, Intensive Care and Emergency Department – Skopje; Department for Anesthesia, Reanimation and Intensive Care – Skopje; University Clinical Center “Mother Theresa” – Skopje.

 

Abstract

Acute hemorrhage results in blood loss followed by consummation of procoagulants, as well as in circulating clotting factors. In acute bleeding, significant amounts of fibrinogen are lost, therefore both cellular and cascade phase of coagulation could be affected leading to coagulopathy. Fluid resuscitation in bleeding patients leads to dilution coagulopathy lowering the levels of circulating coagulation factors including fibrinogen even more further starting a vicious cycle. Many studies have shown that fibrinogen levels below 1g/l in bleeding patients are associated with bleeding and worse outcome suggesting that fibrinogen levels must be measured in trauma patients serving as a threshold for initiation of fibrinogen replacement therapy. Exogenous fibrinogen as a treatment option in critically bleeding patients with low fibrinogen levels has been shown to decrease transfusion needs. Algorithm-based individualized goal-directed use of fibrinogen resulted in highly significant reduction in transfusion needs, adverse outcomes, in certain studies even mortality, and where investigated – reduced costs, with high safety levels at the same time. It has been well established that low fibrinogen levels in patients who undergo cardiac surgery, liver transplantation surgery, in obstetrics, as well as in trauma patients are associated with higher bleeding risk demanding a proactive approach in early fibrinogen supplementation and replacement in order to a better outcome achievement. Although traditionally fibrinogen replacement and supplementation were performed via administration of fresh frozen plasma or cryoprecipitate, the use of lyophilized fibrinogen (concentrate) has become more prevalent in many countries. Recent reports relating to the efficacy of fibrinogen concentrate, suggest that it is a viable alternative to traditional hemostatic approaches, also being a cost-effective when compared to other replacement options which should be considered in a daily practice as well.

 

Key Words: Bleeding; Fibrinogen; Trauma Coagulopathy.

 

References:

  1. Černý V, Maegele M, Agostini V, et al. Variations and obstacles in the use of coagulation factor concentrates for major trauma bleeding across Europe: outcomes from a European expert meeting. Eur J Trauma Emerg Surg. 2022 Apr;48(2):763-774. doi: 10.1007/s00068-020-01563-2. Epub 2021 Jan 5. PMID: 33399876; PMCID: PMC7782571.
  2. Buzzard L, Schreiber M. Trauma-induced coagulopathy: What you need to know. J Trauma Acute Care Surg. 2024 Feb 1;96(2):179-185. doi: 10.1097/TA.0000000000004170. Epub 2023 Oct 13. PMID: 37828662.
  3. Meizoso JP, Moore EE, Pieracci FM, et al. Role of Fibrinogen in Trauma-Induced Coagulopathy. J Am Coll Surg. 2022 Apr 1;234(4):465-473. doi: 10.1097/XCS.0000000000000078. PMID: 35290265.
  4. Spahn DR, Spahn GH, Stein P. Indications and Risks of Fibrinogen in Surgery and Trauma. Semin Thromb Hemost. 2016 Mar;42(2):147-54. doi: 10.1055/s-0035-1564841. Epub 2015 Dec 30. PMID: 26716503.
  5. Kikura, M., Tobetto, Y., Yamamoto, K. et al. Effect of fibrinogen replacement therapy on bleeding outcomes and 1-year mortality in patients undergoing thoracic aortic surgery: a retrospective cohort study. J Anesth 37, 119–129 (2023). https://doi.org/10.1007/s00540-022-03140-w.
  6. Fominskiy E, Nepomniashchikh VA, Lomivorotov VV, et al. Efficacy and Safety of Fibrinogen Concentrate in Surgical Patients: A Meta-Analysis of Randomized Controlled Trials. J Cardiothorac Vasc Anesth. 2016 Oct;30(5):1196-204. doi: 10.1053/j.jvca.2016.04.015. Epub 2016 Apr 16. PMID: 27493092.
  7. Shams Hakimi C, Singh S, Hesse C, Jeppsson A. Effects of fibrinogen and platelet transfusion on coagulation and platelet function in bleeding cardiac surgery patients. Acta Anaesthesiol Scand. 2019 Apr;63(4):475-482. doi: 10.1111/aas.13295. Epub 2018 Dec 3. PMID: 30511382.
  8. Warmuth M, Mad P, Wild C. Systematic review of the efficacy and safety of fibrinogen concentrate substitution in adults. Acta Anaesthesiol Scand. 2012 May;56(5):539-48. doi: 10.1111/j.1399-6576.2011.02586.x. Epub 2011 Dec 12. PMID: 22150561.
  9. Wikkelsø AJ. The role of fibrinogen and haemostatic assessment in postpartum haemorrhage: preparations for a randomised controlled trial. Dan Med J. 2015 Apr;62(4):B5055. PMID: 25872542.
  10. Geck MJ, Singh D, Gunn H, Stokes JK, Truumees E. Relationship Between Preoperative Plasma Fibrinogen Concentration, Perioperative Bleeding, and Transfusions in Elective Adult Spinal Deformity Correction. Spine Deform. 2019 Sep;7(5):788-795. doi: 10.1016/j.jspd.2018.12.001. PMID: 31495480.
  11. Carling MS, Zarhoud J, Jeppsson A, Eriksson BI, Brisby H. Preoperative plasma fibrinogen concentration, factor XIII activity, perioperative bleeding, and transfusions in elective orthopaedic surgery: A prospective observational study. Thromb Res. 2016 Mar;139:142-7. doi: 10.1016/j.thromres.2016.01.001. Epub 2016 Jan 5. PMID: 26916312.
  12. Carrier FM, Deshêtres A, Ferreira Guerra S, et al. Preoperative Fibrinogen Level and Bleeding in Liver Transplantation for End-stage Liver Disease: A Cohort Study. Transplantation. 2023 Mar 1;107(3):693-702. doi: 10.1097/TP.0000000000004333. Epub 2022 Sep 23. PMID: 36150121.
  13. Wikkelsø A, Lunde J, Johansen M, et al. Fibrinogen concentrate in bleeding patients. Cochrane Database Syst Rev. 2013 Aug 29;2013(8):CD008864. doi: 10.1002/14651858.CD008864.pub2. PMID: 23986527; PMCID: PMC6517136.
  14. Abrahamyan L, Tomlinson G, Callum J, et al. Cost-effectiveness of Fibrinogen Concentrate vs Cryoprecipitate for Treating Acquired Hypofibrinogenemia in Bleeding Adult Cardiac Surgical Patients. JAMA Surg. 2023 Mar 1;158(3):245-253. doi: 10.1001/jamasurg.2022.6818. PMID: 36598773; PMCID: PMC9857805.
  15. Cushing MM, Haas T, Karkouti K, Callum J. Which is the preferred blood product for fibrinogen replacement in the bleeding patient with acquired hypofibrinogenemia-cryoprecipitate or fibrinogen concentrate? Transfusion. 2020 Jun;60 Suppl 3:S17-S23. doi: 10.1111/trf.15614. Epub 2020 Jun 1. PMID: 32478877.
  16. Ayaganov D, Kuanyshbek A, Vakhrushev I, Li T. Prospective, Randomized Study of Fibrinogen Concentrate Versus Cryoprecipitate for Correcting Hypofibrinogenemia in Cardiac Surgery Patients. J Cardiothorac Vasc Anesth. 2024 Jan;38(1):80-85. doi: 10.1053/j.jvca.2023.10.031. Epub 2023 Oct 27. PMID: 38016817.
  17. Downey LA, Moiseiwitsch N, Nellenbach K, Xiang Y, Brown AC, Guzzetta NA. Effect of In Vivo Administration of Fibrinogen Concentrate Versus Cryoprecipitate on Ex Vivo Clot Degradation in Neonates Undergoing Cardiac Surgery. Anesth Analg. 2024 Aug 8. doi: 10.1213/ANE.0000000000007123. Epub ahead of print. PMID: 39116012.
  18. Obaid O, Anand T, Nelson A,et al. Fibrinogen supplementation for the trauma patient: Should you choose fibrinogen concentrate over cryoprecipitate? J Trauma Acute Care Surg. 2022 Oct 1;93(4):453-460. doi: 10.1097/TA.0000000000003728. Epub 2022 Jul 15. PMID: 35838235.
  19. Innerhofer N, Treichl B, Rugg C, et al. On Behalf Of The Retic Study Group. First-Line Administration of Fibrinogen Concentrate in the Bleeding Trauma Patient: Searching for Effective Dosages and Optimal Post-Treatment Levels Limiting Massive Transfusion-Further Results of the RETIC Study. J Clin Med. 2021 Aug 31;10(17):3930. doi: 10.3390/jcm10173930. PMID: 34501379; PMCID: PMC8432065.